Skip to main content
68°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
16.42
+0.09 (+0.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
9
Next >
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
March 13, 2023
Via
Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
3 Nasdaq Stocks on Watch This Week
March 12, 2023
These three Nasdaq stocks are poised to make big moves in the coming week.
Via
The Motley Fool
1 Top Biotech Stock to Buy in March
March 07, 2023
This biotech could land a major regulatory approval this month.
Via
The Motley Fool
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed
March 02, 2023
Via
Benzinga
Analysts See Steady Growth For Acadia Pharma's Nuplazid
February 28, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
February 28, 2023
Via
Benzinga
Earnings Preview For ACADIA Pharmaceuticals
February 24, 2023
Via
Benzinga
Analyst Expectations for ACADIA Pharmaceuticals's Future
January 31, 2023
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
December 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Upgrades
Via
Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Via
Benzinga
FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions
August 05, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
September 12, 2022
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory...
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
August 29, 2022
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of...
Via
Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
August 09, 2022
Via
Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
August 09, 2022
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.
Via
Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
August 09, 2022
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...
Via
Benzinga
ACADIA Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
August 08, 2022
Via
Benzinga
8 Analysts Have This to Say About ACADIA Pharmaceuticals
August 05, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
August 05, 2022
Upgrades
Via
Benzinga
Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5
August 05, 2022
CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.